Literature DB >> 10531216

Identification of promiscuous epitopes from the Mycobacterial 65-kilodalton heat shock protein recognized by human CD4(+) T cells of the Mycobacterium leprae memory repertoire.

A S Mustafa1, K E Lundin, R H Meloen, T M Shinnick, F Oftung.   

Abstract

By using a synthetic peptide approach, we mapped epitopes from the mycobacterial 65-kDa heat shock protein (HSP65) recognized by human T cells belonging to the Mycobacterium leprae memory repertoire. A panel of HSP65 reactive CD4(+) T-cell lines and clones were established from healthy donors 8 years after immunization with heat-killed M. leprae and then tested for proliferative reactivity against overlapping peptides comprising both the M. leprae and Mycobacterium tuberculosis HSP65 sequences. The results showed that the antigen-specific T-cell lines and clones established responded to 12 mycobacterial HSP65 peptides, of which 9 peptides represented epitopes crossreactive between the M. tuberculosis and M. leprae HSP65 (amino acids [aa] 61 to 75, 141 to 155, 151 to 165, 331 to 345, 371 to 385, 411 to 425, 431 to 445, 441 to 455, and 501 to 515) and 3 peptides (aa 343 to 355, 417 to 429, and 522 to 534) represented M. leprae HSP65-specific epitopes. Major histocompatibility complex restriction analysis showed that presentation of 9 of the 12 peptides to T cells were restricted by one of the 2 HLA-DR molecules expressed from self HLA-DRB1 genes, whereas 3 peptides with sequences completely identical between the M. leprae and M. tuberculosis HSP65 were presented to T cells by multiple HLA-DR molecules: peptide (aa 61 to 75) was presented by HLA-DR1, -DR2, and -DR7, peptide (aa 141 to 155) was presented by HLA-DR2, -DR7, and -DR53, whereas both HLA-DR2 and -DR4 (Dw4 and Dw14) were able to present peptide (aa 501 to 515) to T cells. In addition, the T-cell lines responding to these peptides in proliferation assays showed cytotoxic activity against autologous monocytes/macrophages pulsed with the same HSP65 peptides. In conclusion, we demonstrated that promiscuous peptide epitopes from the mycobacterial HSP65 antigen can serve as targets for cytotoxic CD4(+) T cells which belong to the human memory T-cell repertoire against M. leprae. The results suggest that such epitopes might be used in the peptide-based design of subunit vaccines against mycobacterial diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531216      PMCID: PMC96942     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Mycobacterium bovis BCG-induced human T-cell clones from BCG-vaccinated healthy subjects: antigen specificity and lymphokine production.

Authors:  A S Mustafa; G Kvalheim; M Degre; T Godal
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

Review 2.  Learning from leprosy: a perspective on immunology and the Third World.

Authors:  B R Bloom
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

3.  HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique.

Authors:  F Vartdal; G Gaudernack; S Funderud; A Bratlie; T Lea; J Ugelstad; E Thorsby
Journal:  Tissue Antigens       Date:  1986-11

4.  BCG-induced suppressor T cells optimal conditions for in vitro induction and mode of action.

Authors:  A S Mustafa; T Godal
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

5.  The tuberculin skin test.

Authors:  D E Snider
Journal:  Am Rev Respir Dis       Date:  1982-03

6.  Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein.

Authors:  S H Kaufmann; U Väth; J E Thole; J D Van Embden; F Emmrich
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

7.  Induction of delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae.

Authors:  H K Gill; A S Mustafa; T Godal
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

Review 8.  Role of heat shock proteins in protection from and pathogenesis of infectious diseases.

Authors:  U Zügel; S H Kaufmann
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Human T-cell clones recognize a major M. leprae protein antigen expressed in E. coli.

Authors:  A S Mustafa; H K Gill; A Nerland; W J Britton; V Mehra; B R Bloom; R A Young; T Godal
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

10.  Human T cell clones recognize two abundant Mycobacterium tuberculosis protein antigens expressed in Escherichia coli.

Authors:  F Oftung; A S Mustafa; R Husson; R A Young; T Godal
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

View more
  16 in total

1.  Matrix metalloproteinase proteolysis of the mycobacterial HSP65 protein as a potential source of immunogenic peptides in human tuberculosis.

Authors:  Sergey A Shiryaev; Piotr Cieplak; Alexander E Aleshin; Qing Sun; Wenhong Zhu; Khatereh Motamedchaboki; Alexander Sloutsky; Alex Y Strongin
Journal:  FEBS J       Date:  2011-08-08       Impact factor: 5.542

2.  A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents.

Authors:  H M Dockrell; S Brahmbhatt; B D Robertson; S Britton; U Fruth; N Gebre; M Hunegnaw; R Hussain; R Manandhar; L Murillo; M C Pessolani; P Roche; J L Salgado; E Sampaio; F Shahid; J E Thole; D B Young
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines.

Authors:  A S Mustafa; F A Shaban; A T Abal; R Al-Attiyah; H G Wiker; K E Lundin; F Oftung; K Huygen
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

4.  Immunopathological evaluation of recombinant mycobacterial antigen Hsp65 expressed in Lactococcus lactis as a novel vaccine candidate.

Authors:  J C Herrera Ramírez; A Ch De la Mora; A De la Mora Valle; G Lopez-Valencia; R M B Hurtado; T B Rentería Evangelista; J L Rodríguez Castillo; A Rodríguez Gardea; S D Gómez Gómez; G E Medina-Basulto
Journal:  Iran J Vet Res       Date:  2017       Impact factor: 1.376

5.  Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides in Mycobacterium bovis BCG-vaccinated healthy subjects.

Authors:  Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

6.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

7.  Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells.

Authors:  Abu S Mustafa; Raja'a Al-Attiyah; Sumaila N M Hanif; Fatema A Shaban
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

8.  Recognition of mycobacterial epitopes by T cells across mammalian species and use of a program that predicts human HLA-DR binding peptides to predict bovine epitopes.

Authors:  Martin Vordermeier; Adam O Whelan; R Glyn Hewinson
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

9.  Synthetic peptides identify promiscuous human Th1 cell epitopes of the secreted mycobacterial antigen MPB70.

Authors:  Raja Al-Attiyah; Fatema A Shaban; Harald G Wiker; Fredrik Oftung; Abu S Mustafa
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Crystal structure of the 65-kilodalton heat shock protein, chaperonin 60.2, of Mycobacterium tuberculosis.

Authors:  Rohini Qamra; Shekhar C Mande
Journal:  J Bacteriol       Date:  2004-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.